The present invention relates to a compound comprising an EZH2 inhibitor and an E3 ligase binder, and a pharmaceutical composition for preventing or treating EZH2-associated disease and a pharmaceutical composition for selective protein degradation containing the same as an active ingredient. Since the compound of the present invention can selectively degrade EZH2, it can be effectively used for the treatment of EZH2-related diseases and cancers, particularly, cancers in which EZH2 is overexpressed, and can be usefully used for the selective degradation of EZH2.
本发明涉及一种包含
EZH2
抑制剂和E3连接酶结合剂的化合物,以及用于预防或治疗
EZH2相关疾病的制药组合物和用作活性成分的选择性蛋白质降解制药组合物。由于本发明中的化合物可以选择性降解
EZH2,因此可以有效地用于治疗
EZH2相关疾病和癌症,特别是
EZH2过度表达的癌症,并可用于选择性降解
EZH2。